Patients with heart failure and preserved ejection fraction have symptomatic and functional improvements with semaglutide across all types, uses, and doses of diuretics, finds the STEP-HFpEF program.
The research from the STEP-HFpEF program was presented here at the Heart Failure Association of the Europe an Society of Cardiology 2024 Congress andSemaglutide"produced consistent beneficial effects on body weight, exercise function, and biomarkers of inflammation and congestion across the subgroups of diuretic use and dose," said study presenter Subodh Verma, MD, PhD, a cardiovascular surgeon at the University of Toronto, Ontario, Canada, and the benefits were"especially large...
Dimitrios T. Farmakis, MD, PhD, from the National and Kapodistrian University of Athens in Greece, who was not involved in the study, commented that the STEP-HFpEF program has been an important step in the treatment of heart failure. The mechanism by which semaglutide promotes changes in plasma volume, natriuresis, and cardiac structure and function data is also currently unclear.
The patients were assessed for diuretic use, type, and dose at weeks 20, 36, and 52, with loop diuretics, thiazide diuretics, and mineralocorticoid receptor agonists all considered as diuretics but not sodium-glucose cotransporter 2 inhibitors. All diuretic doses were converted to
Hypertension Diabetes Diuretics Cardiovascular Imaging Cardiac Imaging CV Imaging Heart Cardiomyopathy Ejection Fraction EF - Ejection Fraction Left Ventricular Ejection Fraction LVEF Obesity Obese Weight Loss Weight Management Europe European Exercise Physical Activity Kidneys Receptors
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Record attendance at 2024 Rochester Heart Ball helps support heart healthRochester, N.Y. — The Rochester Heart Ball is again bringing the community together to save lives and strive for equitable health in Rochester.
Read more »
Ozempic Drug Semaglutide Could Cut Heart Risk By 20%—Regardless Of Weight Loss, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Ozempic Drug Semaglutide Could Cut Heart Risk By 20%—Regardless Of Weight Loss, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Beyond Weight Loss: Semaglutide Delivers Major Heart Health BenefitsScience, Space and Technology News 2024
Read more »
Increasing Evidence Suggests Ozempic (Semaglutide) Helps Curb AlcoholismArianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
Read more »
Xylitol sweetener linked to heart attack and stroke by new study in European Heart JournalA low-calorie sweetener called xylitol used in many reduced-sugar foods and consumer products such as gum and toothpaste may be linked to nearly twice the risk of heart attacks, stroke and death in people who consume the highest levels of the sweetener, a new study found.
Read more »